Lignin-graft-PLGA drug-delivery system improves efficacy of MEK1/2 inhibitors in triple-negative breast cancer cell line

被引：20
|
作者：
Byrne, C. Ethan [1 ]
Astete, Carlos E. [1 ]
Vaithiyanathan, Manibarathi [2 ]
Melvin, Adam T. [2 ]
Moradipour, Mahsa [3 ]
Rankin, Stephen E. [3 ]
Knutson, Barbara L. [3 ]
Sabliov, Cristina M. [1 ]
Martin, Elizabeth C. [1 ]
机构：
[1] Louisiana State Univ, Dept Biol & Agr Engn, Baton Rouge, LA 70803 USA
[2] Louisiana State Univ, Cain Dept Chem Engn, Baton Rouge, LA 70803 USA
[3] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA
来源：
NANOMEDICINE | 2020年 / 15卷 / 10期
基金：
美国国家科学基金会; 美国食品与农业研究所;
关键词：
breast cancer; drug delivery; lignin; nanoparticle; targeted therapies; triple-negative; QUARTZ-CRYSTAL MICROBALANCE; SUPPORTED LIPID-BILAYERS; POLYMERIC NANOPARTICLES; QCM-D; RAS ONCOGENES; MUTANT KRAS; CHEMOTHERAPY; MODEL; RESISTANCE; MEMBRANES;
D O I：
10.2217/nnm-2020-0010
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
Aim: Few targeted therapies are available for triple-negative breast cancer (TNBC) patients. Here, we propose a novel alkaline-lignin-conjugated-poly(lactic-co-glycolic acid) (L-PLGA) nanoparticle drug delivery system to improve the efficacy of targeted therapies. Materials & methods: L-PLGA nanoparticles (NPs) loaded with the MEK1/2 inhibitor GDC-0623 were characterized, tested in vitro on MDA-MB-231 TNBC cell line and compared with loaded PLGA NPs. Results: Loaded L-PLGA NPs were less than half the size of PLGA NPs, had slower drug release and improved the efficacy of GDC-0623 when tested in vitro. We demonstrated that GDC-0623 reversed epithelial-to-mesenchymal transition in TNBC. Conclusion: Our findings indicate that L-PLGA NPs are superior to PLGA NPs in delivering GDC-0623 to cancer cells for improved efficacy in vitro. Graphical abstract
引用
收藏
页码：981 / 1000
页数：20
相关论文
共 36 条
  • [21] Tumor Cell Membrane-Camouflaged Vortex Magnetic Nanoannulars Programmed by Low-Frequency Magnetic Field: A Novel Anti-Cancer Delivery System in Triple-Negative Breast Cancer
    Lu, Yunshu
    Gu, Fenfen
    Ma, Yuwei
    Da, Xianhong
    Li, Ruonan
    Jiang, Lan
    Li, Xiang
    Liu, Yan
    ADVANCED FUNCTIONAL MATERIALS, 2024, 34 (42)
  • [22] Emerging strategies: PARP inhibitors in combination with immune checkpoint blockade in BRCA1 and BRCA2 mutation-associated and triple-negative breast cancer
    Gupta, Tanya
    Vinayak, Shaveta
    Telli, Melinda
    BREAST CANCER RESEARCH AND TREATMENT, 2023, 197 (01) : 51 - 56
  • [23] Para-toluenesulfonamide, a novel potent carbonic anhydrase inhibitor, improves hypoxia-induced metastatic breast cancer cell viability and prevents resistance to αPD-1 therapy in triple-negative breast cancer
    Chen, Hsin-Yuan
    Lin, Chia-En
    Wu, Shun-Chi
    Yang, Zong-Yu
    Chiang, Yi-Fen
    Huang, Ko-Chieh
    Wang, Kai-Lee
    Ali, Mohamed
    Shieh, Tzong-Ming
    Chang, Hsin-Yi
    Huang, Tsui-Chin
    Hsia, Shih-Min
    BIOMEDICINE & PHARMACOTHERAPY, 2023, 167
  • [24] Efficacy of anthracycline/taxane-based neo-adjuvant chemotherapy on triple-negative breast cancer in BRCA1/BRCA2 mutation carriers
    Bignon, Lucie
    Fricker, Jean-Pierre
    Nogues, Catherine
    Mouret-Fourme, Emmanuelle
    Stoppa-Lyonnet, Dominique
    Caron, Olivier
    Lortholary, Alain
    Faivre, Laurence
    Lasset, Christine
    Mari, Veronique
    Gesta, Paul
    Gladieff, Laurence
    Hamimi, Akila
    Petit, Thierry
    Velten, Michel
    BREAST JOURNAL, 2018, 24 (03) : 269 - 277
  • [25] CDK4/6 inhibitors and the pRB-E2F1 axis suppress PVR and PD-L1 expression in triple-negative breast cancer
    Shrestha, Mariusz
    Wang, Dong-Yu
    Ben-David, Yaacov
    Zacksenhaus, Eldad
    ONCOGENESIS, 2023, 12 (01)
  • [26] A phase Ib trial of pembrolizumab plus paclitaxel or flat-dose capecitabine in 1st/2nd line metastatic triple-negative breast cancer
    Page, David B.
    Pucilowska, Joanna
    Chun, Brie
    Kim, Isaac
    Sanchez, Katherine
    Moxon, Nicole
    Mellinger, Staci
    Wu, Yaping
    Koguchi, Yoshinobu
    Conrad, Valerie
    Redmond, William L.
    Martel, Maritza
    Sun, Zhaoyu
    Campbell, Mary B.
    Conlin, Alison
    Acheson, Anupama
    Basho, Reva
    McAndrew, Philomena
    El-Masry, Mary
    Park, Dorothy
    Bennetts, Laura
    Seitz, Robert S.
    Nielsen, Tyler J.
    McGregor, Kimberly
    Rajamanickam, Venkatesh
    Bernard, Brady
    Urba, Walter J.
    McArthur, Heather L.
    NPJ BREAST CANCER, 2023, 9 (01)
  • [27] Blocking LLT1 (CLEC2D, OCIL)-NKRP1A (CD161) interaction enhances natural killer cell-mediated lysis of triple-negative breast cancer cells
    Marrufo, Armando M.
    Chaudhary, Pankaj
    Mathew, Stephen O.
    Malaer, Joseph D.
    Vishwanatha, Jamboor K.
    Mathew, Porunelloor A.
    AMERICAN JOURNAL OF CANCER RESEARCH, 2018, 8 (06): : 1050 - 1063
  • [28] 2D-and 3D-QSAR modelling, molecular docking and in vitro evaluation studies on 18β-glycyrrhetinic acid derivatives against triple-negative breast cancer cell line
    Shukla, Aparna
    Tyagi, Rekha
    Meena, Sanjeev
    Datta, Dipak
    Srivastava, Santosh Kumar
    Khan, Feroz
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2020, 38 (01) : 168 - 185
  • [29] Pharmacological Inhibition of CDK8 in Triple-Negative Breast Cancer Cell Line MDA-MB-468 Increases E2F1 Protein, Induces Phosphorylation of STAT3 and Apoptosis
    Spear, Jensen M.
    Lu, Zhixin
    Russu, Wade A.
    MOLECULES, 2020, 25 (23):
  • [30] Neoadjuvant radiotherapy in ER+, HER2+, and triple-negative -specific breast cancer based humanized tumor mice enhances anti-PD-L1 treatment efficacy
    Bruss, Christina
    Albert, Veruschka
    Seitz, Stephan
    Blaimer, Stephanie
    Kellner, Kerstin
    Pohl, Fabian
    Ortmann, Olaf
    Brockhoff, Gero
    Wege, Anja K.
    FRONTIERS IN IMMUNOLOGY, 2024, 15
1234